BIOMARIN PHARMACEUTICAL INC Proceeds from Issuance of Debt
BIOMARIN PHARMACEUTICAL INC (BMRN) reported Proceeds from Issuance of Debt of $3.65 billion for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfDebt · last filed 2026-08-06
- BIOMARIN PHARMACEUTICAL INC proceeds from issuance of debt for the quarter ending 2026-06-30 was $2.80B.
- BIOMARIN PHARMACEUTICAL INC proceeds from issuance of debt for the quarter ending 2026-03-31 was $850.00M.
- BIOMARIN PHARMACEUTICAL INC proceeds from issuance of debt for the quarter ending 2025-06-30 was $0.00.
- BIOMARIN PHARMACEUTICAL INC proceeds from issuance of debt for the quarter ending 2025-03-31 was $0.00.
| Period end | Proceeds from Issuance of Debt 3 month | Proceeds from Issuance of Debt 6 month |
|---|---|---|
| 2026-06-30 | $2.80B derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $3.65B 10-Q · filed 2026-08-06 |
| 2026-03-31 | $850.00M 10-Q · filed 2026-05-05 | |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $0.00 10-Q · filed 2026-08-06 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |